RIGL Rigel Pharmaceuticals Inc.

2.47
-0.03  -1%
Previous Close 2.50
Open 2.48
Price To book 4.41
Market Cap 307250705
Shares 124,392,998
Volume 302,222
Short Ratio 7.64
Av. Daily Volume 616,407

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 preliminary data released January 5, 2017. Enrollment of second cohort to be completed in 2017 with data due in 2018.
Fostamatinib
IgA nephropathy
Phase 2 trial did not meet endpoints
R348
Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD)
Phase 3 data from the first trial released August 30 2016. Primary endpoint met. Data from second trial did not meet the primary endpoint. PDUFA date April 17, 2018.
Fostamatinib
Immune Thrombocytopenic Purpura (ITP)
Phase 2 data from Stage 1 of trial by end of 2017.
Fostamatinib
Autoimmune hemolytic anemia (AIHA)

Latest News

  1. Rigel to Present at Cantor Fitzgerald Global Healthcare Conference
  2. Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RIGL-US : September 1, 2017
  3. Rigel Welcomes Brian Kotzin, M.D. to Board of Directors
  4. 3 Top Biotech Stocks Under $5
  5. Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  6. Edited Transcript of RIGL earnings conference call or presentation 1-Aug-17 9:00pm GMT
  7. Rigel reports 2Q loss
  8. Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update
  9. Investor Network: Rigel Pharmaceuticals, Inc. to Host Earnings Call
  10. Rigel Announces Conference Call and Webcast to Report Second Quarter 2017 Financial Results
  11. ETFs with exposure to Rigel Pharmaceuticals, Inc. : July 24, 2017
  12. Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RIGL-US : July 24, 2017
  13. Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : July 11, 2017
  14. Rigel Pharmaceuticals, Inc. – Value Analysis (NASDAQ:RIGL) : June 22, 2017
  15. Rigel Announces Oral Presentation of TAVALISSE™ (fostamatinib disodium) Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress
  16. Rigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA
  17. Company News for June 20, 2017
  18. Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RIGL-US : June 20, 2017
  19. Today's Research Reports on Stocks to Watch: Rigel Pharmaceuticals and Bellicum Pharmaceuticals